Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 727-735

  Sportès, Claude ^a   Babb, Rebecca R ^a   Krumlauf, Michael C ^a   Hakim, Frances T ^a   Steinberg, Seth M ^a   Chow, Catherine K ^b   Brown, Margaret R ^b   Fleisher, Thomas A ^b   Noel, Pierre ^b   Maric, Irina ^b   Stetler Stevenson, Maryalice ^a   Engel, Julie ^c   Buffet, Renaud ^c   Morre, Michel ^c   Amato, Robert J ^d   Pecora, Andrew ^e   Mackall, Crystal L ^a   Gress, Ronald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Cytheris Inc   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYT 99007; RECOMBINANT INTERLEUKIN 7; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNITY; BONE MARROW; CANCER OF UNKNOWN PRIMARY SITE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM CARCINOMA; DYSPNEA; ECG ABNORMALITY; EOSINOPHILIA; FEMALE; HEMANGIOPERICYTOMA; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE EROSION; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MONOCYTE; OSTEOSARCOMA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIDE EFFECT; SPLENOMEGALY; SYNOVIAL SARCOMA; T LYMPHOCYTE SUBPOPULATION; THORAX PAIN; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTIGENS, CD3; B-LYMPHOCYTES; BLOOD CELL COUNT; BONE MARROW CELLS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-7; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; SALVAGE THERAPY; YOUNG ADULT;

EID: 74549117108     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1303     Document Type: Article

References (38)

1. Komschlies KL, Grzegorzewski KJ, Wiltrout RH. Diverse immunological and hematological effects of interleukin 7: implications for clinical application. J Leukoc Biol 1995;58:623-33.
2. Hofmeister R, Khaled AR, Benbernou N, et al. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999;10:41-60.
3. Appasamy PM. Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell Mol Ther 1999;5:25-39.
4. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99:3892-904.
5. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-32.
6. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001;97:2983-90.
7. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001;7:73-9.
8. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999;23:783-8.
9. Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected non-human primates. Blood 2003;101:2294-9.
10. Beq S, Nugeyre MT, Ho Tsong FR, et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 2006;176:914-22.
11. Storek J, Gillespy T III, Lu H, et al. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 2003;101:4209-18.
12. Talmadge JE, Jackson JD, Kelsey L, et al. T-cell reconstitution by molecular, phenotypic, and functional analysis in the thymus, bone marrow, spleen, and blood following split-dose polychemotherapy and therapeutic activity for metastatic breast cancer in mice. J Immunother 1993;14:258-68.
13. Komschlies KL, Gregorio TA, Gruys ME, et al. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J Immunol 1994;152:5776-84.
14. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 1996;88:1887-94.
15. Mackall CL, Fry TJ, Bare C, et al. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 2001;97:1491-7.
16. Alpdogan O, Schmaltz C, Muriglan SJ, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 2001;98:2256-65.
17. Broers AE, Posthumus-van Sluijs SJ, Spits H, et al. Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants. Blood 2003;102:1534-40.
18. Alpdogan O, Muriglan SJ, Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest 2003;112:1095-107.
19. Wiryana P, Bui T, Faltynek CR, Ho RJ. Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells. Vaccine 1997;15:561-3.
20. Abdul-Hai A, Ben Yehuda A, Weiss L, et al. Interleukin-7-enhanced cytotoxic T lymphocyte activity after viral infection in marrow transplanted mice. Bone Marrow Transplant 1997;19:539-43.
21. Komschlies KL, Back TT, Gregorio TA, et al. Effects of rhIL-7 on leukocyte subsets in mice: implications for antitumor activity. Immunol Ser 1994;61:95-104.
22. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997;157:167-76.
23. Wang LX, Li R, Yang G, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005;65:10569-77.
24. Li B, Vanroey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 2007;123:155-65.
25. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579-85.
26. Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002;16:1311-8.
27. Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002;117:629-33.
28. Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001;28:865-71.
29. Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-14.
30. Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol 1992;45:770-5.
31. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006;103:2262-7.
32. Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-8.
33. Dittel BN, LeBien TW. The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34. J Immunol 1995;154:58-67.
34. LeBien TW. Fates of human B-cell precursors. Blood 2000;96:9-23.
35. Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol 2005;175:7325-31.
36. + Treg cells. J Exp Med 2006;203:1701-11.
37. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700.
38. + T-regulatory cells. J Immunother 2006;29:313-9.